Cantel Medical Corp.
http://www.cantelmedical.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cantel Medical Corp.
Consistency, Not Fireworks: US FDA’s Novel Approvals Times Stick Close To PDUFA Schedule
CDER holds steady with a median time to approval of 11 months, while CBER posts 10.5 month median review time for its largest novel approvals class.
Stark Warnings For Pharma On Preserving Trust And Overcoming Risk Aversion
Industry veteran Jeremy Levin, the 2023 winner of the Scrip Awards Lifetime Achievement Award, speaks to In Vivo about what holds back innovation in the biopharma industry, new technologies and commitments needed to protect the future relationship between drug developers and patients.
Finance Watch: ReCode’s Series B Mega-Round Grows Again With $50m Boost
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else
Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a recent analysis of FDA approval decisions since 2021.
Company Information
- Industry
-
Medical Devices
- Infection Control-Sterilization
- Other Names / Subsidiaries
-
- Accutron, Inc.
- Aexis Medical BVBA
- Hu-Friedy Corporation
- JetPrep Ltd.
- Medical Innovations Group Holdings Limited,
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice